Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
20.55
-0.13 (-0.63%)
Aug 11, 2026, 9:56 AM EDT - Market open
Anika Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 38.41 | 57.48 | 55.63 | 68.74 | 86.33 | 94.39 |
Cash & Short-Term Investments | 38.41 | 57.48 | 55.63 | 68.74 | 86.33 | 94.39 |
Cash Growth | -27.75% | 3.33% | -19.07% | -20.37% | -8.54% | -4.00% |
Accounts Receivable | 29.06 | 23.69 | 23.59 | 26.36 | 34.63 | 29.84 |
Inventory | 28.57 | 18.79 | 23.81 | 24.43 | 39.77 | 36.01 |
Other Current Assets | 3.15 | 3.4 | 10.62 | 43.78 | 8.83 | 8.29 |
Total Current Assets | 99.19 | 103.36 | 113.65 | 163.31 | 169.55 | 168.53 |
Net Property, Plant & Equipment | 65.05 | 66.26 | 64.68 | 65 | 78.98 | 68.56 |
Other Intangible Assets | 1.65 | 1.65 | 2.49 | 2.58 | 74.6 | 82.38 |
Goodwill | 7.83 | 8.05 | 7.13 | 7.57 | 7.34 | 7.78 |
Other Long-Term Assets | 9.76 | 10.95 | 14.79 | 32.18 | 18.67 | 20.29 |
Total Assets | 183.47 | 190.27 | 202.74 | 270.63 | 349.13 | 347.54 |
Accounts Payable | 6.24 | 6.04 | 5.62 | 6.19 | 9.07 | 7.63 |
Accrued Expenses | 15.91 | 15.87 | 13.57 | 14.07 | 18.84 | 17.85 |
Other Current Liabilities | - | - | 4.12 | 10.8 | - | 4.32 |
Total Current Liabilities | 22.15 | 21.91 | 23.31 | 31.06 | 27.91 | 29.8 |
Long-Term Leases | 23.32 | 24.2 | 24.01 | 25.92 | 28.82 | 19.24 |
Other Long-Term Liabilities | 0.73 | 0.7 | 1.43 | 1.39 | 6.83 | 11.42 |
Total Long-Term Liabilities | 24.05 | 24.9 | 25.45 | 27.31 | 35.65 | 30.66 |
Total Liabilities | 46.19 | 46.81 | 48.75 | 58.37 | 63.57 | 60.45 |
Common Stock | 0.13 | 0.14 | 0.14 | 0.15 | 0.15 | 0.14 |
Additional Paid-in Capital | 83.44 | 87.5 | 88.96 | 90.01 | 81.14 | 67.08 |
Accumulated Other Comprehensive Income | -5.33 | -4.96 | -6.78 | -5.94 | -6.44 | -5.72 |
Retained Earnings | 59.04 | 60.79 | 71.67 | 128.05 | 210.72 | 225.58 |
Shareholders' Equity | 137.28 | 143.47 | 153.99 | 212.27 | 285.56 | 287.09 |
Total Liabilities & Equity | 183.47 | 190.27 | 202.74 | 270.63 | 349.13 | 347.54 |
Total Debt | 23.32 | 24.2 | 24.01 | 25.92 | 28.82 | 19.24 |
Net Cash (Debt) | 15.1 | 33.29 | 31.62 | 42.83 | 57.51 | 75.15 |
Net Cash Growth | -49.67% | 5.28% | -26.18% | -25.54% | -23.47% | -2.96% |
Net Cash Per Share | 1.07 | 2.32 | 2.15 | 2.92 | 3.89 | 5.13 |
Book Value | 137.28 | 143.47 | 153.99 | 212.27 | 285.56 | 287.09 |
Book Value Per Share | 9.75 | 10.01 | 10.46 | 14.48 | 19.31 | 19.62 |
Tangible Book Value | 127.81 | 133.76 | 144.37 | 202.12 | 203.63 | 196.92 |
Tangible Book Value Per Share | 9.07 | 9.33 | 9.81 | 13.79 | 13.77 | 13.46 |